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Background: The spread of drug-resistant tuberculosis (TB) is one of the major public
health problems through the world. Surveillance of anti-TB drug resistance is essential
for monitoring of TB control strategies. The occurrence of drug resistance, particularly
multi-drug resistance Mycobacterium tuberculosis (MDR), defined as resistance to
at least rifampicin (RIF) and isoniazid (INH), has become a significant public health
dilemma. The status of drug-resistance TB in Iran, one of the eastern Mediterranean
countries locating between Azerbaijan and Armenia and high-TB burden countries (such
as Afghanistan and Pakistan) has been reported inconsistently. Therefore, the aim of
this study was to summarize reports of first-line anti-tubercular drug resistance in M.
tuberculosis in Iran.
Material and Methods: We systematically reviewed published studies on
drug-resistant M. tuberculosis in Iran. The search terms were “Mycobacterium
tuberculosis susceptibility” or “Mycobacterium tuberculosis resistant” and Iran.
Results: Fifty-two eligible articles, published during 1998–2014, were included in this
review.Most of the studies were conducted in Tehran. Themost common used laboratory
method for detecting M. tuberculosis drug resistant was Agar proportion. The highest
resistance to first-line drugs was seen in Tehran, the capital city of Iran. The average
prevalence of isoniazid (INH), rifampin (RIF), streptomycin (SM), and ethambotol (EMB)
resistance via Agar proportion method in Tehran was 26, 23, 22.5, and 16%, respectively.
In general, resistance to INH was more common than RIF, SM, and EMB in Tehran
Conclusions: In conclusion, this systematic review summarized the prevalence and
distribution of first-line anti-tubercular drug resistance of M. tuberculosis in Iran. Our
results suggested that effective strategies to minimize the acquired drug resistance, to
control the transmission of resistance and improve the diagnosis measures for TB control
in Iran.
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INTRODUCTION
Tuberculosis (TB) remains as one of themost common infectious
disease in developing countries (Nasiri et al., 2014). In 2012,
∼8.6 million people developed TB and 1.3 million died from
the disease (Organization, 2013). TB is an important health
problem, and this issue has become even more as a result of
increasing number of drug resistant strains (Shamaei et al.,
2009). There is not a complete data about first-line anti-
tubercular drug resistance ofMycobacterium tuberculosis in Iran,
one of the eastern Mediterranean countries locating between
Azerbaijan and Armenia and high-TB burden countries (such
as Afghanistan and Pakistan). Since 1996, when the national
TB control programs established in Iran, TB incidence has
been declining from 34 per 100,000 to 21 per 100,000 cases in
2011(Organization, 2011). Knowledge of geographic variations is
essential for monitoring of antibiotic resistance within a defined
population of patients infected with M. tuberculosis (Bahrmand
et al., 2009). Isoniazid (INH), rifampin (RIF), streptomycin (SM),
and ethambotol (EMB) are first-line chemotherapeutic drugs
used in TB therapy (Mohammadi et al., 2002). Resistant to at
least INH and RIF, is of great concern, because it requires the use
of second-line drugs that are difficult to procure and are much
more toxic and expensive than the first line regimen (Merza et al.,
2011). Based on national wide survey conducted in 1999, among
all M. tuberculosis isolates tested for drug susceptibility, 10.9%
were resistant to = 1 anti-TB drug, and 6.7% were resistant to
both INH and RIF (Organization, 2000). It has been proved that
patients infected with strains resistant to RIF will experience a
higher failure rate with short-course 6 months chemotherapy
(Shamaei et al., 2009). Together with delayed diagnosis and lack
or inadequacy of TB control programs, the emergence of MDR
M. tuberculosis has complicated the epidemiology of TB (Yang
et al., 2011). Although a number of original articles from different
regions of Iran have been published in recent years, there has not
been a systematic review of these data. Therefore, the aim of this
study was to summarize reports on first-line anti-tubercular drug
resistance ofM. tuberculosis in Iran.
MATERIALS AND METHODS
Literature Search
“Mycobacterium tuberculosis susceptibility,” “Mycobacterium
tuberculosis resistant,” “M. tuberculosis susceptibility,” and “M.
tuberculosis resistant” and Iran were searched with special
strategies in PubMed and Google Scholar engines. Three Persian
scientific search engines “Scientific Information Database,”
“IranMedex,” and “MagIran” were searched as well. Reference
articles were explored. Both studies published in English and
Persian were included. Gray literature and Abstracts of articles
which published in congress were not explored. Search strategies
were followed until 30th November 2014.
Inclusion Criteria
We sought any articles of antimicrobial susceptibility testing of
M. tuberculosis isolates. In addition, the bibliography of each
article were reviewed to identify additional relevant articles.
Among English and Persian articles found with mentioned
strategies, those with the following features were included in
the study: (1) Full text was available. (2) An original article was
performed. (3) Susceptibility data for at least one anti- tubercular
drug was available. (4) The laboratory method was used.
Exclusion Criteria
Studies with at least one of the following aspects were excluded:
(1) Studies that were not relevant. (2) Articles with only
available abstracts (without full text). (3) Studies that did not use
laboratory methods (using patients records). (4) Articles that use
of second line of antimicrobial drug resistance. (5) Articles that
were review. (6) Articles which contain no eligible data. (7) Case
series reports. (8) Articles that sample size is too small (N < 10).
Data Collection
At this stage, articles with the following features were excluded
as well: (1) Any articles were published both in English
and Persian. (In these cases, the article published with more
detailed results was chosen). (2) Duplicate publications. For
all studies, we extracted the following data from the original
publications. Literature identification and data extraction was
performed by two researchers independently. Quality assessment
of methodological sections and results of included articles was
performed by use of STROBE checklist (http://www.equator-
network.org).
RESULTS
A total of 15,979 articles were achieved by literature search using
different combination of key terms from the databases (Figure 1).
After exclusion based on title not relevant and duplicates, 74
articles were retrieved for detailed full-text evaluation. Finally
52 studies, 24 in English, and 28 in Persian, addressing the
prevalence of drug resistance TB were included (Tables 1, 2).
The original articles were performed in different places of
Iran. Most studies were conducted in Tehran (n = 25;
Bahrmand et al., 2000; Mohammadi et al., 2002; Seyed-Davood
Mansoori et al., 2003; Masjedi et al., 2006; Mirsaeidi et al., 2007;
Mohammadzadeh et al., 2007; Farnia et al., 2008a,b; Shamaei
et al., 2009; Dinmohammadi et al., 2010; Merza et al., 2011;
Ostadzadeh et al., 2011; Sheikholslami et al., 2011; Taghavi et al.,
2011; Tasbiti et al., 2011; Derakhshani Nezhad et al., 2012;
Marjani et al., 2012; Mohammadi, 2012; Tahmasebi et al., 2012;
Bahrami et al., 2013; Ali et al., 2014; Nasiri et al., 2014; Sheikh
Ghomi et al., 2014; Varahram et al., 2014; Velayati et al., 2014)
and Tabriz (n = 8; HassanHeidarnejad andNagili, 2001;Moadab
and Rafi, 2006; Varshochi et al., 2006; Asgharzadeh et al., 2007,
2014; Rafi et al., 2009; Roshdi and Moadab, 2009; Zamanlou
et al., 2009). Other studies were performed in Khorasan (n = 3;
Namaei et al., 2006; Velayati et al., 2014; Sani et al., 2015), Ardebil
(n = 1; Velayati et al., 2014), Isfahan (n = 3; Moniri, 2001;
Nasiri et al., 2014; Velayati et al., 2014), Mazandaran (n = 3;
Pourhajibagher et al., 2012; Babamahmoodi et al., 2014; Velayati
et al., 2014), Gilan (n = 1; Velayati et al., 2014), Hamadan (n = 1;
Velayati et al., 2014), Kerman(n = 1; Velayati et al., 2014),
Kurdistan(n = 1; Velayati et al., 2014), Yazd (n = 1; Velayati
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FIGURE 1 | Flow diagram of study identification.
et al., 2014), Qazvin (n = 1; Velayati et al., 2014), Kermanshah
(n = 4; Izadi et al., 2011; Nasiri et al., 2014; Velayati et al., 2014;
Mohajeri et al., 2014), Golestan (n = 3; Javid et al., 2009; Livani
et al., 2011; Velayati et al., 2014), Markazi (n = 3; Farazi et al.,
2013; Taherahmadi et al., 2013; Velayati et al., 2014), Lorestan
(n = 1; Velayati et al., 2014), Khuzestan (n = 2; Khosravi
et al., 2006; Velayati et al., 2014), Sistan va Baluchistan (n = 5;
Bostanabad et al., 2007; Bahrmand et al., 2009; Haeili et al., 2013;
Nasiri et al., 2014; Velayati et al., 2014), Qom (n = 1; Velayati
et al., 2014), Fars (n = 1; Velayati et al., 2014), Hormozgan (n =
2; Nasiri et al., 2014; Velayati et al., 2014), and Semnan (n = 1;
Velayati et al., 2014). A study which was conducted by Velayati
et al. (2014), in years 2010–2011, has been investigated drug
resistant in various places in Iran (Tehran, Sistan ba Balochestan,
Khozestan, Khorasan, Ardebil, Qom, Golestan, Isfahan, Gilan,
Fars, Hormozgan, Mazandaran, Semnan, Lorestan, Hamedan,
Kerman, Kordestan, Kermanshah, Markazi, Yazd, and Qazvin
(Velayati et al., 2014), but we identified it as 1 study in search
flow diagram, it was considered for Nasiri et al. study too (Nasiri
et al., 2014). In Isfahan, 4 surveys were performed but in one
of them (Tavakoli et al.) only abstract was available, and it was
excluded from total records. One study which was conducted
by Moaddab et al. (2011) that did not note the location. One
study has been done in Tehran and Zabol (Zakerbostanabad
et al., 2008). One study has been conducted by Haeili et al.
(2013) in Tehran, Alborz, Sistan va Blochestan, Hormozgan, and
Kermanshah. Another study had been done in Tehran-Arak by
Taheri et al. (2013). The reference method for determining drug
resistance of M. tuberculosis was agar proportion. Using this
method, the mean of resistance to INH, RIF, SM and EM in
Iran was 20, 18, 18%, and to EM is 12%, respectively. Despite
the reference method for susceptibility test is agar proportion
(Rieder et al., 1998), the method that was used in most of the
cities were PCR. For this reason, we determine the mean of
resistance to INH and RIF in different geographical regions based
on this method too. If Iran is divided into 8 geographical regions
(Table 3), themean of resistance to INH inNorthern provinces of
country was 5%, and maximum resistance was seen in Golestan
and the minimum resistance was belonged to Gilan province.
The mean of resistance to RIF was 4%, and the maximum
and minimum resistance was seen in Gilan and Mazandaran,
respectively. The mean of resistance to INH and RIF in Southern
provinces of Iran was 6.45 and 10%, respectively. The mean of
resistance to INH in Western provinces of country was 5%, and
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the maximum resistance belonged to Kordestan and minimum
resistance was seen in Lorestan. The mean of resistance to RIF
was 11%, and the highest and lowest resistance was seen in
Lorestan and Kordestan. The mean of resistance to INH and
RIF in Northwest provinces of Iran was 6.5 and 3%, respectively.
The mean of resistance to INH in central provinces of country
was 9%, and maximum resistance belonged to Markazi while
minimum resistance belong to Yazd that no resistance has been
seen. The mean of resistance to RIF was 10%, and the highest
and lowest level of resistance was seen in Markazi and Qom.
One of the provinces of central regions is Isfahan. In Isfahan
the mean of resistance to INH based on agar proportion was
12.6% which was similar to PCR method (12%), but mean of
resistance to RIF based on agar proportion was 26%, that was
higher than PCR method (7%). In Markazi provinces, the mean
of resistance to INH, based on reference method was 2.6% that
was lower than PCR; there was the same result about RIF too.
In Southwest of Iran, resistance to INH and RIF was 6 and
5%, respectively. The mean of resistance to INH and RIF in
Northeast provinces of Iran was 4%. In Southeast provinces
of Iran such as Sistan- Blochestan and Kerman, the mean of
resistance to INH and RIF was 4.4 and 9% based on PCRmethod.
Because the most of method that use in Sistan- Blochestan was
agar proportion, we calculate the mean of resistance to INH
and RIF based on the mentioned method, (INH 20% and RIF
12%). Due to the large number of studies in Tehran and Tabriz,
these provinces were examined separately. The most common
laboratory method that used was agar proportion in Tehran. The
average prevalence of resistant against INH in Tehran was 26%,
RIF 23%, SM 22.5%, and EMB 16% by agar proportion method.
In general, resistance to INH was more common than RIF, SM
and EMB in Tehran. The average prevalence of resistant against
INH in Tabriz was 15%, RIF 5%, SM 19%, and EMB 2.43% by
agar proportion. The highest resistance to first-line drugs was
seen in Tehran. Most studies about two drug resistances were
conducted in Tehran by proportional method on INH and RIF.
The mean of resistance to INH and RIF in Tehran was 22% by
proportional method. The mean of resistance to INH and RIF
in IRAN was 15% by this method. Due to the limited number
of studies on other two drug resistance, the results are given
only in Table 2. Most studies on three drug resistance were
conducted on INH, RIF and SM. The mean of resistance to
these three drugs was 4% using proportional method. The mean
of resistance to all first line drugs in IRAN was 3.57% by this
method.
DISCUSSION
This review addressed the prevalence of first-line anti-tubercular
drug resistance of M. tuberculosis in Iran. Various types of
methods were used for determination of the susceptibility of
M. tuberclusis: agar proportion (reference method), different
types of PCR (PCR-RFLP, Real time PCR, PCR-SSCP, MAS-
PCR, and Allele specific PCR), MGMT, and MGIT (direct and
indirect). But most of them that used were agar proportion
or PCR. In all the studies that use both of them, the results
of reference method (agar proportion) had the highest of
sensitivity and specificity (Javid et al., 2009; Sheikholslami et al.,
2011; Derakhshani Nezhad et al., 2012; Mohammadi, 2012;
Taherahmadi et al., 2013). In this study, evaluation of first-line
anti-tubercular drug resistance in various provinces of Iran was
based on PCR method that is not very accurate. It seems that
the prevalence of drug resistance is higher than the results of
studies that use mentioned method (PCR). As can be seen in
the Table 1, the highest resistance of M. tuberculosis to first line
drugs was observed in Tehran, INH:26%, RIF:23%, SM:22.5%,
and EMB:16%. This could be due to transferring of patients
with treatment failure to referral Hospitals in Tehran. The other
reason could be presence of different nations such as Afghan,
Iraq and Pakistan in Tehran. Between 1996 to 2000, three studies
have been conducted in Tehran, Mohammadi et al. (2002),
Bahrmand et al. (2000), and Seyed-Davood Mansoori et al.
(2003) reported the resistance prevalence of 46.6, 6.2, and 28%
to isoniazid, respectively. The reason of this difference could
be due to small sample size in first study (Mohammadi et al.,
2002). In Mohamadi et al. study, M. tuberculosis was isolated
from referral patients that can be the reason of high resistance
to isoniazid in this study. Two studies have been conducted
in 2010–2011, in Velayati et al. (2014) reports, the prevalence
of isoniazid resistance was 6% and in Tahmasebi et al. (2012)
this level was 70.1%, that the reason of this difference could
be used to strains that isolate from patients with treatment
failure in second study. Over the years the increasing level of
resistance to isoniazid might be due to incomplete treatment.
The failure treatment can be for two reason, inappropriate drug
prescribing and drug usage regularly and on time. This process
has been seen about rifampin resistance. During 2000 and 2008,
Shamaei et al. (2009) and Merza et al. (2011) reported the highest
prevalence of rifampin resistance. These studies have been done
in Masih daneshvari Hospital that is a referral hospital in Iran
and most of the patients refer to this hospital due to treatment
failure. As mentioned in results, high prevalence of resistance
to INH (20%) and RIF (12%) was seen in Sistan va Blochestan
due to vicinity of this province to Afghanistan and Pakistan.
Rifampin and isoniazid resistance is a surrogate marker for
MDR- M. tuberculosis. Most of studies reporting isoniazid and
rifampin resistance were conducted in Tehran. These studies
report the highest prevalence of resistance to INH and RIF (22%).
In Masjedi et al. (2008) study, among 77% Iranian and 23%
afghan cases, 131 Iranian (65%), and 13 afghan cases (22%)
were susceptible to all 4 drugs tested and 72 patients (28%)
were MDR-TB case. Notably, 38 MDR-TB cases (52.7%) were
isolated from afghan immigrants. Twenty patients (47%) had
mono drug resistant strains (nine were INH, seven SM, three
RF, and one EMB mono resistant) and 22 (52%) had combined
resistance.
In Al-Akhali et al. (2007) study that was performed in Yemen,
the prevalence of resistance to any one of the four drugs was
9.8% in the new cases and 17.4% in the previously treated
cases. The prevalence of MDR-TB, defined as TB cases excreting
M. tuberculosis resistant at least to INH and RIF, was 3%. In Ayaz
et al. (2012) study that conducted in Pakistan, resistance to one or
more of the first-line anti-TB drugs was noted in 23% of patients.
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TABLE 1 | Summary of studies on resistance to a single drug among Mycobacterium tuberculosis isolates in Iran.
Study Resistance to a single drug
Location Author Years Method No. of isolates
tested
INH RIF SM EMB
N % N % N % N %
Ardebil Velayati et al., 2014 2010–2011 PCR(a) 65 2 3 4 6 … … … …
Fars Velayati et al., 2014 2010–2011 PCR(a) 40 2 5 5 12.5 … … … …
Gilan Velayati et al., 2014 2010–2011 PCR(a) 39 1 2.5 2 5 … … … …
Golestan Javid et al., 2009 2008 PCR(b) 87 6 7 4 5 … … … …
Agar proportion 45 4 9 6 13 … … … …
Livani et al., 2011 … MGIT 148 26 18 5 3 … … … …
Velayati et al., 2014 2010–2011 PCR(a) 47 3 6 2 4 … … … …
Qom Velayati et al., 2014 2010–2011 PCR(a) 61 3 5 3 5 … … … …
Hormozgan Velayati et al., 2014 2010–2011 PCR(a) 38 3 8 3 8 … … … …
Nasiri et al., 2014 2010–2012 Agar proportion 48 3 6 2 4 4 8 2 4
Hamedan Velayati et al., 2014 2010–2011 PCR(a) 21 1 5 2 10 … … … …
Isfahan Velayati et al., 2014 2010–2011 PCR(a) 42 5 12 3 7 … … … …
Nasiri et al., 2014 2010–2012 Agar proportion 45 2 7 2 9 1 2 0 0
Moniri, 2001 1998–2009 Agar proportion 94 17 18 41 44 14 15 3 3
Khorasan Namaei et al., 2006 2001–2002 indirect proportion 105 1 1 … … 27 26 … …
Velayati et al., 2014 2010–2011 PCR(a) 117 10 8.5 9 8 … … … …
Sani et al., 2015 2012–2013 Agar proportion 100 7 7 7 7 9 9 3 3
Kermanshah Izadi et al., 2011 2006–2008 Agar proportion 14 8 57 6 43 … … … …
Velayati et al., 2014 2010–2011 PCR(a) 16 1 6 2 12.5 … … … …
Nasiri et al., 2014 2010–2012 Agar proportion 15 4 26.6 3 20 3 20 3 20
Mohajeri et al., 2014 2011–2012 Agar proportion 112 18 16 16 14 25 22 15 13
Kermanshah Mohajeri et al., 2015 2011–2013 Agar proportion 125 … … 35 28 … … … …
Khozestan Khosravi et al., 2006 2001 PCR(c) 80 5 6 6 7.5 … … … …
Velayati et al., 2014
2010–2011 PCR(a) 119 7 6 3 2.5 … … … …
Kerman Velayati et al., 2014 2010–2011 PCR(a) 24 1 4 3 12.5 … … … …
Kordestan Velayati et al., 2014 2010–2011 PCR(a) 16 2 12.5 0 0 … … … …
Lorestan Velayati et al., 2014 2010–2011 PCR(a) 24 0 0 5 21 … … … …
Mazandaran Pourhajibagher et al.,
2012
2010–2011 PCR(d) 59 4(use of katG
gene)
3(use of inhA
gene)
7
5
1 2 … … … …
Velayati et al., 2014 2010–2011 PCR(a) 26 1 4 1 4 … … … …
Babamahmoodi et al.,
2014
… LPA(e) 54 2 4 3 5.5 4 7 … …
Markazi Taherahmadi et al., 2013 … Agar proportion
PCR-RFLP (f)
60 … … … … … … 43
19
72
32
(Continued)
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TABLE 1 | Continued
Study Resistance to a single drug
Location Author Years Method No. of isolates
tested
INH RIF SM EMB
N % N % N % N %
Farazi et al., 2013 2011–2012 Agar proportion 115 3 3 2 2 3 3 8 7
Velayati et al., 2014 2010–2011 PCR(a) 15 3 20 3 20 … … … …
Qazvin Velayati et al., 2014 2010–2011 PCR(a) 10 1 10 0 0 … … … …
Semnan Velayati et al., 2014 2010–2011 PCR(a) 21 0 0 0 0 … … … …
Zakerbostanabad et al.,
2008
2005–2006 Agar proportion 91 28 31 4 4 23 25 8 9
Sistan va
Balochestan
Bahrmand et al., 2009 2005–2006 Agar proportion 286 … … 78 27 … … … …
Velayati et al., 2014 2010–2011 PCR(a) 165 8 5 10 6 … … … …
Nasiri et al., 2014 2010–2012 Agar proportion 59 5 8 3 5 8 13.5 3 5
Tehran Ostadzadeh et al., 2011 … Agar proportion 50 … … 25 50 … … … …
Farnia et al., 2008a … Agar proportion
MGMT Both of
them
60 0
0
30
0
0
50
0
0
30
0
0
50
4
3
29
7
5
48
3
5
28
5
8
47
Sheikholslami et al., 2011 … Agar proportion
PCR-SSCP(g)
74 17
10
23
13.5
7
4
9
5
… … … …
Seyed-Davood Mansoori
et al., 2003
1996–2000 Agar proportion 273 76 28 50 18.5 50 18.5 28 10
Bahrmand et al., 2000 1998–1999 Agar proportion 563 35 6 25 4 55 10 17 3
Mohammadi et al., 2002 1999–2000 MGIT Direct MGIT
in Direct Agar
proportion
15 10
10
7
67
67
47
11
11
8
73
73
53
5
6
7
33
40
47
5
5
5
33
33
33
Dinmohammadi et al.,
2010
1999–2008 Agar proportion 90 52 58 … … … … … …
Shamaei et al., 2009 2000–2003 Agar proportion 548 152 28 119 22 184 34 75 14
Merza et al., 2011 2000–2005 Agar proportion 1742 414 24 307 18 478 27 207 12
Mirsaeidi et al., 2007 2003–2004 Agar proportion 264 93 35 52 20 96 36 35 13
Marjani et al., 2012 2003–2008 Agar proportion 554 81 15 27 5 116 21 22 4
Varahram et al., 2014 2003–2011 Agar proportion
and Allele specific
PCR
4825 296 6 … … … … … …
Farnia et al., 2008b 2006–2007 Agar proportion 258 9 3 3 1 7 3 1 0.4
Mohammadi, 2012 2006–2008 Agar proportion
MAS-PCR(h)
90 … … 37
29
41
32
… … … …
Tasbiti et al., 2011 2006–2009 Agar proportion 1027 116 11 110 11 232 23 104 10
Taghavi et al., 2011 2008–2009 Agar proportion
MAS-PCR(i)
96 56
43
58
45
… … … …
Ali et al., 2014 2009–2011 Agar proportion
PCR-SSCP
103 12
5
12
5
9
4
9
4
… … … …
Velayati et al., 2014 2010–2011 PCR(a) 324 20 6 26 8
Derakhshani Nezhad
et al., 2012
2010–2011 Agar proportion
Allele-specific PCR
106 … … … … … … 36
13
34
28
(Continued)
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TABLE 1 | Continued
Study Resistance to a single drug
Location Author Years Method No. of isolates
tested
INH RIF SM EMB
N % N % N % N %
Tahmasebi et al., 2012 2010–2011 Agar proportion 97 68 70 63 65 28 29 47 48
Bahrami et al., 2013 2010–2012 Agar proportion 176 … … … … … … 48 27
Nasiri et al., 2014
2010–2012 Agar proportion 85 6 7 7 8 14 16 6 7
Sheikh Ghomi et al.,
2014
2012–2013 Agar proportion
and Multiplex PCR
83 35 42 47 56 … … … …
Tabriz Zamanlou et al., 2009 2005–2007 Agar proportion 50 25 50 … … … … … …
Rafi et al., 2009 … Agar proportion 90 6 7 3 3 17 19 … …
Moadab and Rafi, 2006 1999–2003 Agar proportion 90 7 8 2 2 17 19 … …
Asgharzadeh et al., 2007 … Agar proportion
MAS-PCR(j)
120 13 11 12 10 27 22.5 4
10
3
8
Roshdi and Moadab,
2009
… Agar proportion 103 2 2 0 0 8 8 0 0
Varshochi et al., 2006 2003–2004 Agar proportion 90 20 22 9 10 28 31 5 5.5
Hassan Heidarnejad and
Nagili, 2001
… Agar proportion 155 12 8 1 1 20 13 0 0
Asgharzadeh et al., 2014 … Agar proportion 120 13 11 12 10 27 22.5 4 3
Yazd Velayati et al., 2014 2010–2011 PCR(a) 12 0 0 1 8 … … … …
Tehran-Arak Taheri et al., 2013 … Agar proportion 40 … … 20 50 … … … …
Tehran–
Alborz-
Sistan va
Blochestan-
Hormozgan-
Kermanshah
Haeili et al., 2013 2010–2012 Agar proportion 291 4 1 2 1 21 7 2 1
Tehran-
Zabol-
Kermanshah-
Mashad-
Tabriz
Bostanabad et al., 2011 2007–2008 Agar proportion 163 42 26 38 23 38 23 12 7
Unknown Moaddab et al., 2011 … Agar proportion
and MIC
50 25 50 … … … … … …
(a): Multiplex-PCR assay for detection of mutations in RRDR(Rifampin resistance determinant region), and PCR assay for detection of mutations in IRDR (Isoniazid resistance determinant
region) of katG, inhA.
(b): PCR assay for detection of mutations in RRDR of rpoB and IRDRof katG and inhA.
(c): PCR assay for detection of mutations in RRDR of rpoB and IRDR of katG.
(d): PCR assay for detection of mutations in RRDR of rpoB and IRDR of katG and inhA.
(e): Line Probe Assay.
(f): PCR-RFLP assay for detection of mutations in ERDR (Ethambotol resistance determinant region) of embB.
(g): PCR-SSCP assay for detection of mutations in RRDR of rpoB, ahpC and IRDR of katG, inhA.
(h): Mass-PCR assay for detection of mutations in RRDR of rpoB.
(i): Mass-PCR assay for detection of mutations in IRDR of katG.
(j): MAS-PCR assay for detection of mutations in ERDR of embB.
MGIT, Mycobacterium growth indicator tube; MIC, minimum inhibitory concentration; MGMT, malachite green microtube.
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TABLE 3 | Different geographical regions of Iran.
Region Provinces
North Golestan, Gilan, Mazandaran
South Fars, Hormozgan
West Kordestan, Kermanshah, Lorestan, Hamedan
Center Isfahan, Qom, Markazi, Yazd
Northeast Khorasan, Semnan
Northwest Ardebil, Ghazvin
Southeast Sistan-Blochestan, Kerman
Southwest Khozestan
The INH resistance was 9% in untreated and 28.5% in treated
patients. Resistance to other first-line drugs was as follow: SM
17%, EMB 5%, and RIF 5%.
Some limitations of this systematic review should be
considered for results interpretation. First, few studies have
been conducted in our country about resistance of TB to first
and second line-drugs. Second, the probable influence of age,
sex, ethnicity, economic level, and life styles could not be
analyzed due to the limited information obtained from the
original articles. Third, most included studies were hospital-
based rather than population based which makes the results
more prone to potential selection bias. Because of the small
number of studies particularly in other cities except Tehran,
we cannot judge about the prevalence of resistance against
first-line anti-tuberculosis drugs properly. However, in recent
years, emergence and spread of MDR-TB threaten the TB
control strategy. In many law-and middle-income countries, due
to inadequate laboratory capacity, most of the patients with
MDR-TB are not diagnosed. Treatment of these cases mostly
failed and significant expenditure of health care resources is
needed.
In conclusion, this systematic review summarized the
prevalence and distribution of first-line anti-tubercular drug
resistance ofM. tuberculosis in Iran. Our results suggest effective
strategies to minimize the acquired drug resistance, to control the
transmission of resistance and improve the diagnosis measures
for TB control in our country.
An important element in gaining control of this epidemic
is developing an understanding of the molecular basis of
resistance to the most important anti-tuberculosis drugs. Since
the mechanism of action of rifampin is to inhibit mycobacterial
transcription by targeting DNA-dependent RNA polymerase
(Somoskovi et al., 2001), routine application of rapid molecular
tests in the clinical management of drug-resistant tuberculosis is
highly recommended.
On the other hand, INH is activated by the mycobacterial
enzyme KatG, a multifunctional catalase-peroxidase that
has other activities including peroxynitritase and NADH
oxidase. Therefore, inhibition of both cell wall lipid, and
nucleic acid synthesis by INH-NAD and INH-NAPD adducts
together with respiratory inhibition by INH-derived NO can
provides a potent antituberculosis cocktail. Some strategies
such as developing agents that produce the isonicotinoyl
radical, screening for molecules which increase mycobacterial
levels of NAD+ or NADP+ for in co-administration use
with INH, to designing of more drug-like molecules using
the structure of INH-NAD adducts to inhibit specifically
mycobacterial enzymes; and developing of mycobacterial
enzyme inhibitors which can inactivate INH might be useful to
control INH-TB resistance propagation (Timmins and Deretic,
2006).
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